Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts.
Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts. J Hematol Oncol. 2013 Oct 29; 6(1):81.